

Pembrolizumab KEYNOTE-859

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE

OS



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Other adjustments



Pembrolizumab KEYNOTE-859

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE


1




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: Pembrolizumab with fluoropyrimidine and platinum-containing ChT for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.
 Experimental Arm: Pembrolizumab + Fluoropyrimidine + platinum-containing ChT
 Control Arm: Placebo + fluoropyrimidine + platinum-containing ChT



